Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could shorter antibiotic courses be safer for ventilator pneumonia?

NCT ID NCT05545735

Disease control Sponsor: University of Miami Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether giving antibiotics for 4 days instead of the usual 7 days is safe and effective for patients with ventilator-associated pneumonia (VAP). The goal was to reduce side effects from antibiotics while still treating the infection. The trial was stopped early after enrolling only 27 surgical patients, so the findings are limited.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
antibiotics
What this could lead to
If successful, this could show that a shorter course of antibiotics is safe and effective for early ventilator-associated pneumonia, reducing side effects and antibiotic resistance.
What could go wrong
The trial was terminated early with only 27 participants, so results are limited and may not be reliable. Shorter treatment might not clear the infection in all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

27 people

The number who actually took part.

Started

May 2023

Finished

Feb 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Surgical patient 2. Early VAP, defined as VAP occurring within 2 - 7 days of intubation (via endotracheal or tracheostomy tube) (9). VAP will be defined according to local institutional protocol. 3. Hospital length of stay (LOS) \< 10 days at the time of VAP diagnosis. 4. Patients are willing to provide informed consent or their Legally Authorized Representative (LAR) is willing to provide informed consent on their behalf when the patient is unable (i.e., cognitively impaired from sedation on a ventilator) Exclusion Criteria: 1. Age \< 18 years 2. Prior episode of VAP for the index admission 3. VAP caused by any of the following pathogens: * Methicillin-resistant Staphylococcus aureus (MRSA) * Vancomycin-intermediate Staphylococcus aureus (VISA) * Pseudomonas aeruginosa * Vancomycin-resistant Enterococcus (VRE) * Acinetobacter baumanii * Stenotrophomonas maltophilia * Carbapenem-resistant Enterobacteriaceae (CRE) * Extended-spectrum beta lactamase-producing gram-negative bacilli 4. Causative pathogen not sensitive to choice of initial empiric antibiotic 5. Antibiotic therapy for \> 5 of the last 10 days preceding VAP diagnosis 6. Septic shock, defined as evidence of tissue hypoperfusion after adequate volume expansion, due to infection, and requiring \> 1 vasopressor (17) 7. Current or recent (within 30 days) use of immunosuppressive medications 8. LOS \> 72 hours at a transferring facility 9. Pregnancy or lactation 10. Legal arrest or incarceration 11. Moribund state in which death is imminent 12. ECMO (Extracorporeal membrane oxygenation) 13. Extubation prior to randomization

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ventilator associated pneumonia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Pneumonia, Ventilator-Associated

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ventilator associated pneumonia

Contacts and locations

Locations

  • Jackson Memorial Hospital

    Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.